logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals receives US FDA clearance for Phase 2b/3 human study

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with major news for the company that they have received clearance from the U.S. FDA for its multinational Phase 2b/3 study of Ifenprodil as a potential treatment for COVID-19.

Moreau talks about how big this milestone is for the company and how the study is to be conducted.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.235 CAD

CSE:AGN
Market: CSE
Market Cap: $21.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

iCoreConnect cloud-based software is a real game changer in healthcare

iCoreConnect (OTCQB: ICCT) President and CEO Robert McDermott joined Steve Darling from Proactive to discuss the company that provides HIPAA-compliant software for the medical and dental industries. McDermott discusses a few of their services, their recent revenue growth and why listing on...

13 hours, 29 minutes ago

2 min read